Contraceptive vaginal ring
- Jennifer Kerns, MD, MPH
Jennifer Kerns, MD, MPH
- Assistant Professor
- University of California, San Francisco
- Philip D Darney, MD, MSc
Philip D Darney, MD, MSc
- University of California, San Francisco
Combined (estrogen-progestin) hormonal contraception is a popular method of contraception worldwide  and is highly effective when used consistently and correctly . The contraceptive vaginal ring offers the same benefits as oral contraceptives (OCs), but has the advantage that daily user compliance is not required [3,4]. The ring is left in place for three weeks and then removed for a single ring-free week.
Formulation — The contraceptive vaginal ring is a flexible device measuring 54 mm in diameter and 4 mm in cross-section (picture 1). The outer ring is composed of ethinyl estradiol (EE) and an ethylene vinyl acetate copolymer that contains crystals of etonogestrel (ENG), the 3 keto-metabolite of desogestrel. The device is latex-free.
Pharmacokinetics — The ring releases 15 mcg of EE and 120 mcg of ENG per day . There is an immediate increase in serum hormonal concentration after insertion with a slow decrease over the cycle . The concentration of EE is lower with the vaginal ring compared to other combined hormonal contraceptives:
●In one study, the maximum serum concentration of EE was 30 percent lower than desogestrel-containing oral contraceptives (OCs) (34.7 ± 17.5 ng/L versus 124.9 ± 46.3 ng/L) and systemic exposure to EE was half that of desogestrel-containing OCs .
●In a randomized trial comparing a levonorgestrel-containing OC, transdermal patch, and vaginal ring, users of the vaginal ring experienced 3.4 times lower EE exposure than patch users, and 2.1 times lower EE exposure than OC users . Exposure to EE in the ring, OC, and patch groups were 10.6 ± 2.5 ng-h/mL, 21.9 ± 2.9 ng-h/mL, and 35.8 ± 5.5 ng-h/mL, respectively. These differences were not all proportional to differences in EE dose of the three contraceptives: 30 mcg/day for the OC, 20 mcg/day for the patch, and 15 mcg/day for the ring.
- Blackburn RD, Cunkelman A, Zlidar VM. Oral contraceptives--an update. Popul Rep A 2000; :1.
- Nanda K. Contraceptive patch and vaginal contraceptive ring. In: Contraceptive Technology, 19th edition, Hatcher RA, Trussell, J, et al. (Eds), Ardent Media, New York 2007. p.271.
- Hatcher R, Trussell J, Stewart F. Contraceptive Technology, 18th ed, Ardent Media, Inc, New York 2004.
- Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002; 100:585.
- Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet 2000; 39:233.
- van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 2005; 72:168.
- Duijkers IJ, Klipping C, Verhoeven CH, Dieben TO. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study. Hum Reprod 2004; 19:2668.
- Killick S. Complete and robust ovulation inhibition with NuvaRing. Eur J Contracept Reprod Health Care 2002; 7 Suppl 2:13.
- Mulders TM, Dieben TO. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril 2001; 75:865.
- Dragoman M, Petrie K, Torgal A, et al. Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women. Contraception 2013; 87:432.
- Trussell J. Contraceptive failure in the United States. Contraception 2011; 83:397.
- Lopez LM, Grimes DA, Gallo MF, et al. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev 2013; :CD003552.
- Gilliam ML, Neustadt A, Kozloski M, et al. Adherence and acceptability of the contraceptive ring compared with the pill among students: a randomized controlled trial. Obstet Gynecol 2010; 115:503.
- Gupta N, Corrado S, Goldstein M. Hormonal contraception for the adolescent. Pediatr Rev 2008; 29:386.
- Piccinino LJ, Mosher WD. Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect 1998; 30:4.
- Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
- Nuva Ring Package Insert: Patient Information. Organon USA, Inc, 2008.
- Barreiros FA, Guazzelli CA, Barbosa R, et al. Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects. Contraception 2010; 81:223.
- Miller L, Verhoeven CH, Hout Ji. Extended regimens of the contraceptive vaginal ring: a randomized trial. Obstet Gynecol 2005; 106:473.
- Barreiros FA, Guazzelli CA, de Araújo FF, Barbosa R. Bleeding patterns of women using extended regimens of the contraceptive vaginal ring. Contraception 2007; 75:204.
- Guazzelli CA, Barreiros FA, Barbosa R, et al. Extended regimens of the vaginal contraceptive ring: cycle control. Contraception 2009; 80:430.
- Barreiros FA, Guazzelli CA, Barbosa R, et al. Extended regimens of the combined contraceptive vaginal ring containing etonogestrel and ethinyl estradiol: effects on lipid metabolism. Contraception 2011; 84:155.
- Etonogestrel and ethinyl estradiol insert, extended release. US Food & Drug Administration (FDA) approved product information. Revised November, 2014. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on November 19, 2014).
- Nuvaring. US Food & Drug Administration (FDA) approved product information. Revised 12/2013. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on November 13, 2014).
- Mulders TM, Dieben TO, Bennink HJ. Ovarian function with a novel combined contraceptive vaginal ring. Hum Reprod 2002; 17:2594.
- Roumen FJ, Apter D, Mulders TM, Dieben TO. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum Reprod 2001; 16:469.
- Merki-Feld GS, Hund M. Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages. Eur J Contracept Reprod Health Care 2007; 12:240.
- Ahrendt HJ, Nisand I, Bastianelli C, et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006; 74:451.
- Roumen FJ, op ten Berg MM, Hoomans EH. The combined contraceptive vaginal ring (NuvaRing): first experience in daily clinical practice in The Netherlands. Eur J Contracept Reprod Health Care 2006; 11:14.
- Schafer JE, Osborne LM, Davis AR, Westhoff C. Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive. Contraception 2006; 73:488.
- Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial. Hum Reprod 2005; 20:557.
- Stuart JE, Secura GM, Zhao Q, et al. Factors associated with 12-month discontinuation among contraceptive pill, patch, and ring users. Obstet Gynecol 2013; 121:330.
- Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception 2006; 74:220.
- Oddsson K, Leifels-Fischer B, de Melo NR, et al. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. Contraception 2005; 71:176.
- Bjarnadóttir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002; 186:389.
- Vercellini P, Barbara G, Somigliana E, et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril 2010; 93:2150.
- Westhoff C, Osborne LM, Schafer JE, Morroni C. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive. Obstet Gynecol 2005; 106:89.
- Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptives. Obstet Gynecol 2004; 104:555.
- Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone. Hum Reprod 2006; 21:2304.
- O'Connell KJ, Osborne LM, Westhoff C. Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. Contraception 2005; 72:323.
- Massaro M, Di Carlo C, Gargano V, et al. Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. Contraception 2010; 81:209.
- Guida M, Di Spiezio Sardo A, Bramante S, et al. Effects of two types of hormonal contraception--oral versus intravaginal--on the sexual life of women and their partners. Hum Reprod 2005; 20:1100.
- Sulak PJ, Smith V, Coffee A, et al. Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol 2008; 112:563.
- Dinger J, Möhner S, Heinemann K. Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring. Obstet Gynecol 2013; 122:800.
- FDA Office of Surveillance and Epidemiology. Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf (Accessed on February 03, 2012).
- Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366:2257.
- Battaglia C, Genazzani AD, Artini PG, et al. Ultrasonographic and color Doppler analysis in the treatment of polycystic ovary syndrome. Ultrasound Obstet Gynecol 1998; 12:180.
- Cagnacci A, Ferrari S, Tirelli A, et al. Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study. Contraception 2009; 80:34.
- Abu Hashim H, Alsherbini W, Bazeed M. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. Contraception 2012; 85:246.
- Sivin I, Mishell DR Jr, Alvarez F, et al. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial. Contraception 2005; 71:122.
- Brache V, Massai R, Mishell DR, et al. Ovarian function during use of Nestorone(R) subdermal implants. Contraception 2000; 61:199.
- Massai R, Quinteros E, Reyes MV, et al. Extended use of a progesterone-releasing vaginal ring in nursing women: a phase II clinical trial. Contraception 2005; 72:352.
- RamaRao S, Clark H, Merkatz R, et al. Progesterone vaginal ring: introducing a contraceptive to meet the needs of breastfeeding women. Contraception 2013; 88:591.
- Nath A, Sitruk-Ware R. Progesterone vaginal ring for contraceptive use during lactation. Contraception 2010; 82:428.
- Massai R, Miranda P, Valdés P, et al. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception 1999; 60:9.
- Caucus on New and Underused Reproductive Technologies. Progesterone-only vaginal ring: a technical brief. In: Reproductive Health Supplies Coalition, 2009.
- Mechanism and duration of action
- - Adolescents
- - Postpartum and postabortion
- Initiation and use
- Reinsertion after unintended removal
- Return of fertility
- Cycle control
- SIDE EFFECTS
- No effect on bone mineral density
- Improved psychosexual function
- Unscheduled bleeding
- Serious complications
- - Toxic shock
- - Cardiovascular and thromboembolic events
- NON-CONTRACEPTIVE BENEFITS
- NEW DEVELOPMENTS IN VAGINAL RINGS
- Nestorone and ethinyl estradiol combined hormonal vaginal ring
- Progesterone-releasing vaginal ring
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS